

December 7, 2023

Press Release

TOWA PHARMACEUTICAL CO., LTD.

Listing of Two Ingredients and Four Items of New Products (New Generics) in the NHI Drug Price Standard

Towa Pharmaceutical Co., Ltd. (Head office: Kadoma, Osaka; President and Representative Director: Itsuro Yoshida; hereinafter, the “Company”) announces that it will start selling two ingredients and four items of new products (new generics) on December 8, the effective date of their listing in the NHI Drug Price Standard, following public notice in the official gazette on December 7.

As a result, the number of the Company’s products will be 339 ingredients and 780 items.

Product name	Therapeutic category	Brand-name/ representative drugs
OSELTAMIVIR TABLETS 75mg “TOWA”	Anti-influenza virus drug	TAMIFLU Capsules 75
LEVOCARNITINE FF ORAL SOLUTION 10% “TOWA” / 10% 5mL “TOWA” / 10% 10mL “TOWA”	Levocarnitine preparation	L-Cartin FF oral solution 10% / 10% 5mL packs / 10% 10mL packs

[Inquiries]

Public Relations and Investor Relations Department, Towa Pharmaceutical Co., Ltd.

2-11 Shinbashi-cho, Kadoma, Osaka 571-8580, Japan

Tel: +81-6-6900-9102 / Fax: +81-6-7177-4960 / Email: kouhou@towayakuhin.co.jp

1 / 1